Alexion Pharmaceuticals Inc (ALXN)

ALXN (NASDAQ:Drugs)
$156.01
pos +3.78
+2.48%
Today's Range: 150.10 - 163.50 | ALXN Avg Daily Volume: 1,975,800
Last Update: 04/24/14 - 4:00 PM EDT
Volume: 3,372,349
YTD Performance: 14.56%
Open: $158.35
Previous Close: $152.23
52 Week Range: $87.01 - $185.43
Oustanding Shares: 197,830,376
Market Cap: 30,881,321,694
6-Month Chart
TheStreet Ratings Grade for ALXN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 13 14 16 15
Moderate Buy 1 1 1 1
Hold 3 3 3 3
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.38 1.36 1.33 1.34
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 142.47
Price Earnings Comparisons:
ALXN Sector Avg. S&P 500
142.47 123.30 29.23
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
10.36% 66.03% 205.19%
GROWTH 12 Mo 3 Yr CAGR
Revenue 36.80 1.87 0.42
Net Income -0.80 1.61 0.37
EPS -1.40 1.35 0.32
Earnings for ALXN:
EBITDA 0.60B
Revenue 1.55B
Average Earnings Estimates
Qtr (03/14) Qtr (06/14) FY (12/14) FY (12/15)
Average Estimate $1.09 $0.90 $4.01 $5.11
Number of Analysts 5 5 5 5
High Estimate $1.21 $0.95 $4.35 $5.79
Low Estimate $0.72 $0.81 $3.37 $4.65
Prior Year $0.58 $0.65 $2.75 $4.01
Growth Rate (Year over Year) 87.59% 38.77% 45.67% 27.56%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Jim Cramer

 | Apr 14, 2014 | 11:49 AM EDT

Cautionary tales that the IPO window might be closing at last.

By

Scott Redler

 | Apr 3, 2014 | 6:43 PM EDT

Intel  breaks above our target on Piper Jaffray upgrade.

By

Scott Redler

 | Apr 1, 2014 | 6:12 PM EDT

Ford rallies after March auto sales blow past Street view, surpassing our target.

By

Scott Redler

 | Mar 31, 2014 | 6:03 PM EDT

Alaska Air is trading above all key moving averages with a healthy uptrend since July.

bullishAlexion estimates, target increased at Credit Suisse

Mar 27, 2014 | 8:14 AM EDT

ALXN estimates were raised through 2016, Credit Suisse said. Expect higher Soliris sales. Neutral rating and new $171 price target. 

bullishAlexion Pharmaceuticals price target, EPS boosted at UBS

Mar 11, 2014 | 7:49 AM EDT

ALXN raised its number, USB said. Well-positioned with faster ramp of sales in France and opportunity to lever the operating model. $202 price target and Buy rating.

bullishAlexion Pharmaceuticals price target, EPS boosted at Jefferies

Jan 31, 2014 | 8:21 AM EST

ALXN shares now reaching $145, Jefferies said. Driven by strong Soliris sales and significantly lower tax rates. Hold rating. 

By

Jim Cramer

 | Jan 30, 2014 | 12:50 PM EST

These types of companies are winners today.

bearishAlexion downgraded at Goldman

Jan 6, 2014 | 8:30 AM EST

ALXN was downgraded from Buy to Neutral, Goldman Sachs said. Valuation call, based on a $140 price target. 

By

Scott Redler

 | Oct 1, 2013 | 6:54 PM EDT

Maintain a stock-specific approach until a clearer trend develops.

CH Robinson has had a higher gap opening the last four days in a row. Boy, someone really ...
The wicked, whipsaw action following FB's earnings release last evening warns me the stock...
This stock has been a dog for years, but its ears are perking here lately, and today has m...
Good afternoon! Oil has taken a swift turn this week and is showing further weakness ahead...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.